Compounds > ave 9488
Page last updated: 2024-11-12

ave 9488

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-fluoro-N-indan-2-yl-benzamide: nitric oxide synthase transcription enhancer that ameliorates portal hypertension [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10131276
SCHEMBL ID248645
MeSH IDM0520895

Synonyms (18)

Synonym
AKOS002332222
n-(2,3-dihydro-1h-inden-2-yl)-4-fluorobenzamide
n-(2,3-dihydro-1h-inden-2-yl)-2,2-difluoro-1,3-benzodioxole-5-carboxamide
ave-9488
unii-9u46kwj9uf
4-fluoro-n-(indan-2-yl)benzamide
291756-32-6
9u46kwj9uf ,
ave 9488
benzamide, n-(2,3-dihydro-1h-inden-2-yl)-4-fluoro-
SCHEMBL248645
4-fluoro-n-(indan-2-yl)-benzamide
BOFMSBVSYVESTM-UHFFFAOYSA-N
4-fluoro-n-(indan-2-yl) benzamide
n-(indan-2-yl)-4-fluoro-benzamide
4-fluoro-n-indan-2-yl-benzamide
ave-308
PD160567

Research Excerpts

Treatment

ExcerptReferenceRelevance
"AVE 9488-treated rats had higher liver NOS-3 mRNA and protein levels, whereas NOS-3 mRNA and protein in the aorta and the SMA did not vary between groups."( Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension.
Biecker, E; Heller, J; Hennenberg, M; Kang, A; Sauerbruch, T; Trebicka, J, 2008)		1.29

Bioavailability

ExcerptReferenceRelevance
"Reduced endothelial nitric oxide (NO) bioavailability contributes to the progression of heart failure."( Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction.
Bauersachs, J; Ertl, G; Fraccarollo, D; Galuppo, P; Hoffmann, M; Ruetten, H; Thum, T; Tsikas, D; Widder, JD, 2008)		0.35
"Increased risk of thrombo-embolic events in congestive heart failure (CHF) has been attributed to a hypercoagulable state including vascular endothelial dysfunction and reduced bioavailability of nitric oxide (NO) as well as platelet activation."( Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer.
Bauersachs, J; Eigenthaler, M; Ertl, G; Fraccarollo, D; Schäfer, A; Widder, J, 2009)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (85.71)29.6817
2010's0 (0.00)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.09 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index13.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		2.3110D-glucopyranoseepitope;
mouse metabolite
cardiovascular agents
Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.		2.0410
ConditionIndicatedRelationship StrengthStudiesTrials
Cardiac Remodeling, Ventricular
[description not available]		02.0410
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.4520
Cardiovascular Stroke
[description not available]		02.0410
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		02.0410
Cardiac Failure
[description not available]		02.0510
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		02.0510
Injury, Myocardial Reperfusion
[description not available]		02.0510
Cruveilhier-Baumgarten Syndrome
Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS.		02.4520
Cirrhosis, Liver
[description not available]		02.0510
Hypertension, Portal
Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.		02.4520
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		02.0510
Atherogenesis
[description not available]		02.0410
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		02.0410
Bile Duct Obstruction, Extrahepatic
[description not available]		02.0410
Biliary Cirrhosis
[description not available]		02.0410
Liver Cirrhosis, Biliary
FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.		02.0410